sirolimus and wye

sirolimus has been researched along with wye* in 1 studies

Other Studies

1 other study(ies) available for sirolimus and wye

ArticleYear
Rapamycin and WYE-354 suppress human gallbladder cancer xenografts in mice.
    Oncotarget, 2015, Oct-13, Volume: 6, Issue:31

    Gallbladder cancer (GBC) is a highly malignant tumor characterized by a poor response to chemotherapy and radiotherapy. We evaluated the in vitro and in vivo antitumor efficacy of mTOR inhibitors, rapamycin and WYE-354. In vitro assays showed WYE-354 significantly reduced cell viability, migration and invasion and phospho-P70S6K expression in GBC cells. Mice harboring subcutaneous gallbladder tumors, treated with WYE-354 or rapamycin, exhibited a significant reduction in tumor mass. A short-term treatment with a higher dose of WYE-354 decreased the tumor size by 68.6% and 52.4%, in mice harboring G-415 or TGBC-2TKB tumors, respectively, compared to the control group. By contrast, treatment with a prolonged-low-dose regime of rapamycin almost abrogated tumor growth, exhibiting 92.7% and 97.1% reduction in tumor size, respectively, compared to control mice. These results were accompanied by a greater decrease in the phosphorylation status of P70S6K and a lower cell proliferation Ki67 index, compared to WYE-354 treated mice, suggesting a more effective mTOR pathway inhibition. These findings provide a proof of concept for the use of rapamycin or WYE-354 as potentially good candidates to be studied in clinical trials in GBC patients.

    Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Drug Therapy, Combination; Gallbladder Neoplasms; Guanine; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred NOD; Mice, SCID; Phosphorylation; Signal Transduction; Sirolimus; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2015